API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under Licensing agreement with Sirona, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 (Difluorocyclohexyloxyphenol) and related compounds.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allergan Aesthetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 13, 2022
Details:
Under the terms of the agreement, Sirona will manufacture and supply TFC-1067 (difluorocyclohexyloxyphenol), a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorporating the ingredient.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: RODAN & FIELDS LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 16, 2022
Details:
Sirona has made its first shipment of compound, TFC-1067 to Rodan + Fields. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia.
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020